Epidermal growth factor receptor tyrosine kinase inhibitor–resistant disease
Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here,
we present an update on new controversies and conclusions regarding the disease …
we present an update on new controversies and conclusions regarding the disease …
Targeted cancer therapies in the twenty‐first century: lessons from imatinib
F Stegmeier, M Warmuth, WR Sellers… - Clinical Pharmacology …, 2010 - Wiley Online Library
An increased understanding of the molecular etiology of cancer has enabled the
development of novel therapies that are collectively referred to as molecular targeted …
development of novel therapies that are collectively referred to as molecular targeted …
Optimization of dosing for EGFR-mutant non–small cell lung cancer with evolutionary cancer modeling
Non–small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth
factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib …
factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib …
“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
C Grommes, GR Oxnard, MG Kris, VA Miller… - Neuro …, 2011 - academic.oup.com
Erlotinib is effective for epidermal growth factor receptor (EGFR) mutant lung cancer, but
CNS penetration at standard daily dosing is limited. We previously reported that intermittent …
CNS penetration at standard daily dosing is limited. We previously reported that intermittent …
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant …
JL Clarke, W Pao, N Wu, VA Miller… - Journal of neuro …, 2010 - Springer
Leptomeningeal metastases (LM) occur in 5–10% of patients with solid tumors and are
associated with a dismal prognosis. We describe LM from lung adenocarcinoma harboring a …
associated with a dismal prognosis. We describe LM from lung adenocarcinoma harboring a …
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis
JL Kuiper, LE Hendriks, AJ van der Wekken… - Lung cancer, 2015 - Elsevier
Objectives Development of leptomeningeal metastasis (LM) in non-small cell lung cancer
(NSCLC)-patients is associated with a poor prognosis. It has been suggested that LM …
(NSCLC)-patients is associated with a poor prognosis. It has been suggested that LM …
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis
NP Shah, C Kasap, C Weier, M Balbas, JM Nicoll… - Cancer cell, 2008 - cell.com
The BCR-ABL inhibitor dasatinib achieves clinical remissions in chronic myeloid leukemia
(CML) patients using a dosing schedule that achieves potent but transient BCR-ABL …
(CML) patients using a dosing schedule that achieves potent but transient BCR-ABL …
ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium
SJ Fuller, K Sivarajah, PH Sugden - Journal of molecular and cellular …, 2008 - Elsevier
The epidermal growth factor (EGF) receptor (or ErbB1) and the related ErbB4 are
transmembrane receptor protein tyrosine kinases which bind extracellular ligands of the …
transmembrane receptor protein tyrosine kinases which bind extracellular ligands of the …
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
M Santarpia, A Liguori, N Karachaliou… - Lung Cancer: Targets …, 2017 - Taylor & Francis
The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
G Chen, P Kronenberger, E Teugels, IA Umelo… - BMC medicine, 2012 - Springer
Background The epidermal growth factor receptor (EGFR) is a validated therapeutic target in
non-small cell lung cancer (NSCLC). However, current single agent receptor targeting does …
non-small cell lung cancer (NSCLC). However, current single agent receptor targeting does …